These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 18434391

  • 21. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardière JL, Pacanowski J, Meynard JL, Hance AJ, Clavel F, Mammano F.
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [Abstract] [Full Text] [Related]

  • 22. The binding mode of fusion inhibitor T20 onto HIV-1 gp41 and relevant T20-resistant mechanisms explored by computational study.
    Qiu S, Yi H, Hu J, Cao Z, Wu Y, Li W.
    Curr HIV Res; 2012 Mar; 10(2):182-94. PubMed ID: 22339124
    [Abstract] [Full Text] [Related]

  • 23. Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort.
    Peuchant O, Capdepont S, Ragnaud JM, Aurillac-Lavignolle V, Thiébaut R, Fleury H, Masquelier B, ANRS CO3 Aquitaine Cohort.
    Antivir Ther; 2007 Mar; 12(4):559-62. PubMed ID: 17668565
    [Abstract] [Full Text] [Related]

  • 24. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.
    Chong H, Yao X, Zhang C, Cai L, Cui S, Wang Y, He Y.
    PLoS One; 2012 Mar; 7(3):e32599. PubMed ID: 22403678
    [Abstract] [Full Text] [Related]

  • 25. Development of resistance to VIR-353 with cross-resistance to the natural HIV-1 entry virus inhibitory peptide (VIRIP).
    Gonzalez E, Ballana E, Clotet B, Esté JA.
    AIDS; 2011 Aug 24; 25(13):1557-83. PubMed ID: 21572303
    [Abstract] [Full Text] [Related]

  • 26. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
    Xiong S, Borrego P, Ding X, Zhu Y, Martins A, Chong H, Taveira N, He Y.
    J Virol; 2017 Jan 01; 91(1):. PubMed ID: 27795437
    [Abstract] [Full Text] [Related]

  • 27. A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability.
    Pan C, Cai L, Lu H, Lu L, Jiang S.
    J Biol Chem; 2011 Aug 12; 286(32):28425-34. PubMed ID: 21690094
    [Abstract] [Full Text] [Related]

  • 28. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D, Ding X, Liu Z, Wu X, Zhu Y, Wei H, Chong H, Cui S, He Y.
    J Biol Chem; 2018 Aug 17; 293(33):12703-12718. PubMed ID: 29929981
    [Abstract] [Full Text] [Related]

  • 29. Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.
    Baatz F, Nijhuis M, Lemaire M, Riedijk M, Wensing AM, Servais JY, van Ham PM, Hoepelman AI, Koopmans PP, Sprenger HG, Devaux C, Schmit JC, Perez Bercoff D.
    PLoS One; 2011 Aug 17; 6(7):e21535. PubMed ID: 21760896
    [Abstract] [Full Text] [Related]

  • 30. Mutation L33M in the HR1 region of HIV-1 gp41 may play a role in T20 resistance.
    Chong H, Xu S, Zhang C, Nie J, Wang Y.
    J Clin Virol; 2009 Jul 17; 45(3):255-8. PubMed ID: 19487156
    [Abstract] [Full Text] [Related]

  • 31. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L.
    J Virol; 2017 Jan 01; 91(1):. PubMed ID: 27795416
    [Abstract] [Full Text] [Related]

  • 32. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
    Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW.
    J Virol; 2005 Apr 01; 79(8):4991-9. PubMed ID: 15795284
    [Abstract] [Full Text] [Related]

  • 33. Compensatory mutations rescue the virus replicative capacity of VIRIP-resistant HIV-1.
    González-Ortega E, Ballana E, Badia R, Clotet B, Esté JA.
    Antiviral Res; 2011 Dec 01; 92(3):479-83. PubMed ID: 22027647
    [Abstract] [Full Text] [Related]

  • 34. In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.
    Liu Z, Shan M, Li L, Lu L, Meng S, Chen C, He Y, Jiang S, Zhang L.
    J Biol Chem; 2011 Feb 04; 286(5):3277-87. PubMed ID: 21098485
    [Abstract] [Full Text] [Related]

  • 35. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides.
    Lohrengel S, Hermann F, Hagmann I, Oberwinkler H, Scrivano L, Hoffmann C, von Laer D, Dittmar MT.
    J Virol; 2005 Aug 04; 79(16):10237-46. PubMed ID: 16051817
    [Abstract] [Full Text] [Related]

  • 36. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
    Su Y, Chong H, Qiu Z, Xiong S, He Y.
    J Virol; 2015 Jun 04; 89(11):5801-11. PubMed ID: 25787278
    [Abstract] [Full Text] [Related]

  • 37. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.
    Naito T, Izumi K, Kodama E, Sakagami Y, Kajiwara K, Nishikawa H, Watanabe K, Sarafianos SG, Oishi S, Fujii N, Matsuoka M.
    Antimicrob Agents Chemother; 2009 Mar 04; 53(3):1013-8. PubMed ID: 19114674
    [Abstract] [Full Text] [Related]

  • 38. Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients.
    Carmona R, Pérez-Alvarez L, Muñoz M, Casado G, Delgado E, Sierra M, Thomson M, Vega Y, Vázquez de Parga E, Contreras G, Medrano L, Nájera R.
    J Clin Virol; 2005 Mar 04; 32(3):248-53. PubMed ID: 15722032
    [Abstract] [Full Text] [Related]

  • 39. Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion.
    He Y.
    Curr Pharm Des; 2013 Mar 04; 19(10):1800-9. PubMed ID: 23092277
    [Abstract] [Full Text] [Related]

  • 40. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).
    Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR.
    J Virol; 2004 May 04; 78(9):4628-37. PubMed ID: 15078945
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.